Together with Eli Lilly and NIAID’s Vaccine Research Center, AbCellera’s Pandemic Prevention Platform team combined microfluidics, data science, machine learning, bioinformatics, and genomics to bring the first COVID-19 antibody to clinical trials in under 90 days, a process that typically requires three to six years. In June Eli Lilly began two Phase 1 clinical trials of COVID-19 antibodies isolated by AbCellera. “People have pushed themselves to the very limits of their endurance in this race against the virus,” says AbCellera head of R&D Ester Falconer.
Recognize your brand’s excellence by applying to this year’s Brands That Matter Awards before the early-rate deadline, May 3.